



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/26 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2023/082587

(22) International Filing Date:

05 December 2023 (05.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/430,075 05 December 2022 (05.12.2022) US

(71) Applicant: **BIOGATE PRECISION MEDICINE CORP.** [CN/CN]; 10F., No. 70, Sec. 3, Nanjing E. Rd., Zhongshan Dist., Taipei City, 104 (TW).

(72) Inventor; and

(71) Applicant (for TZ only): **LIU, Fong Leroy** [US/US]; 3713 GREENFIELD AVE., LOS ANGELES, California 90034-7003 (US).

(72) Inventors: **HUANG, Chong-Jen Frank**; 10F., No. 70, Sec. 3, Nanjing E. Rd., Zhongshan Dist., Taipei City, 104 (TW).
HO, Chia-Wen; 10F., No. 70, Sec. 3, Nanjing E. Rd., Zhongshan Dist., Taipei City, 104 (TW).

(74) Agent: **NAN Z. CARR**; NZ CARR LAW OFFICE, PLLC, 2101 CityWest Blvd. STE 100, Houston, Texas 77042 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: RECOMBINANT ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF IN TREATING CANCERS




Fig. 5

(57) Abstract: Disclosed herein are recombinant antibodies or a fragment thereof. According to some embodiments of the present disclosure, each of the recombinant antibodies exhibits a binding affinity to and a neutralizing effect on parathyroid hormone-related protein. Also disclosed herein are pharmaceutical compositions comprising the antibodies or antibody fragments, and uses thereof in treating cancers.